Growth Hormone
Tesamorelin
A stabilised GHRH analog researched extensively in HIV-associated lipodystrophy for its visceral-fat-reducing properties.
Quick facts
Molecular weight
5,189 Da
Half-life
0.4 h
Frequency
daily
Admins / wk
7
Routes
SubQ
Typical dose
1.00 mg–2.00 mg
Mechanism & positioning
A stabilised GHRH analog researched extensively in HIV-associated lipodystrophy for its visceral-fat-reducing properties.
Researched for: visceral adipose reduction, IGF-1 elevation.
Reconstitution defaults
Default vial
5 mg
BAC water
2 mL
Concentration
2500 mcg/mL
Doses per vial
~5
Other stocked vial sizes: 10, 20 mg.
Calculate with this peptide
Dosage Calculator
Pre-filled for 1.00 mg from a 5 mg vial in 2 mL BAC water.
Reconstitution Calculator
Auto-fills 5 mg + 2 mL BAC water + 1.00 mg target dose.
Half-Life Calculator
Simulates steady-state at 1.00 mg daily.
Pen & Cartridge Calculator
Loads the Tesamorelin 20 mg pen preset (20 mg / 3 mL).
Peptide Chemistry Calculator
Loads the published sequence — MW, pI, net charge vs pH, hydrophilicity.
Documented pairwise interactions
- warning
Tesamorelin + CJC-1295 (no-DAC)
Both are GHRH analogs targeting the same receptor; combination provides no additive benefit and may downregulate receptor sensitivity.
- warning
Tesamorelin + CJC-1295 (with DAC)
Both are GHRH analogs at the same receptor; the DAC long-acting form already maintains baseline stimulation.
- caution
Tesamorelin + Ipamorelin
GHRH + GHRP class combination; common research pairing but ensure dose ranges are conservative.
- warning
Tesamorelin + Sermorelin
Two GHRH analogs at the same receptor; combination is redundant.
References
- Falutz J et al., NEJM, 2007.
- Falutz J et al., Clin Endocrinol, 2010.
Related peptides in the Growth Hormone class
CJC-1295 (no-DAC)
A growth-hormone-releasing-hormone analog researched for its ability to stimulate endogenous pulsatile GH secretion, often paired with a GHRP.
CJC-1295 (with DAC)
CJC-1295 conjugated to a Drug Affinity Complex linker that binds serum albumin, extending half-life to roughly eight days and producing a steady GHRH-axis baseline rather than pulsatile peaks.
Ipamorelin
A selective ghrelin-mimetic pentapeptide investigated for triggering GH release with minimal off-target hormonal effects.
Sermorelin
The original 1-29 amino-acid fragment of GHRH; researched for restoring pulsatile growth-hormone secretion via direct hypothalamic-pituitary axis stimulation.
Hexarelin
A six-amino-acid growth-hormone-releasing peptide investigated for potent acute GH release and ancillary cardiovascular research models.
IGF1-LR3
A long-acting IGF-1 analog with an extended N-terminal sequence and an arginine substitution that reduces IGF-binding-protein affinity, producing a substantially longer circulating half-life than native IGF-1.